Clinical Study of Umbilical Cord Mesenchymal Stem Cells Infusion for Aging Frailty

Shanghai East Hospital30 enrolled

Overview

The purpose of this clinical study is to answer the questions: 1. Is the proposed intervention safe? 2. Is the proposed intervention effective in improving the healthy status of subjects with aging frailty?

Aging frailty is a clinical syndrome, characterized by a decrease of homeostatic reserves and enhanced vulnerability to endogenous or exogenous stressors, exposing individuals to an increased risk of adverse health-related outcomes. The human umbilical cord (HUC) is a promising source of mesenchymal stem cells (MSCs), compared to embryonic stem cells, HUC-MSCs are noncontroversial with a painless collection procedure and faster self-renewal properties. HUC-MSCs can differentiate into the different germ layers and modulate immune responses. One possible mechanism for the onset and development of aging frailty is the depletion of stem cells. Hence, intravenous infusion of HUC-MSCs is attractive therapy against aging frailty. This is a randomized, double-blind, placebo-controlled clinical trial. The participants (n = 30) will be randomly distributed into two groups. The HUC-MSCs Group (n = 15) will receive intravenous infusion of mesenchymal stem cells twice over a month (30 days interval), the Control Group (n = 15) will receive the same protocolized intervention with normal saline. Follow-up duration is 6 months after first intervention. The reported serious adverse events（SAEs）will be observed within one month post infusion. The short-item from health survey（SF-36), EuroQol five dimensions questionnaire (EQ-5D) and Fried phenotype scale will be evaluated. Short physical performance battery (SPPB) and plasm biomarkers will be assessed.The assessments will be performed at baseline, 1 month, 3 months and 6 months. The intent of this study is to explore domains of efficacy of HUC-MSCs through the reduction of signs and symptoms of aging frailty and to evaluate the safety of HUC-MSCs in subjects with aging frailty.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Aging Frailty

Interventions

Human umbilical cord mesenchymal stem cells（HUC-MSCs）BIOLOGICAL

Human umbilical cord mesenchymal stem cells（HUC-MSCs）

PlaceboBIOLOGICAL

Placebo

Eligibility

Sex: ALLMin age: 60 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects age ≥60 and ≤80 years at the time of signing the informed consent form. 2. Must show signs of frailty apart from a concomitant condition as assessed by the investigator with a frailty score of 1 to 4 using the Fried Phenotype Scale. 3. Must provide written informed consent. 4. Subjects are expected to live more than 12 months. Exclusion Criteria: 1. Serious comorbid illness that, in the opinion of the investigator, may compromise the safety or compliance of the patient or preclude successful completion of the study 2. Advanced liver or renal failure, class III/IV congestive heart failure, myocardial infarction, unstable angina, cardiac revascularization, or severe obstructive ventilator defect. 3. Uncontrolled hypertension or hyperglycemia. 4. Have known allergies to biological drugs or antibiotics. 5. Expecting to receive organ transplantation. 6. Have a clinical history of malignancy or active autoimmune diseases. 7. Have a history of drug or alcohol abuse within the past 24 months. 8. Be serum-positive for HIV, hepatitis BsAg or viremic hepatitis C. 9. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial. 10. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods.

Locations (1)

Shanghai East Hospital, Shanghai Tongji University

Shanghai, China

Outcomes

Primary Outcomes

Safety of HUC-MSCs infusion

Safety were assessed by incidence of reported serious adverse events (SAEs) within one month after infusion. An SAE is defined as any untoward medical occurrence that: 1. Results in death 2. Is life-threatening (stroke or non-fatal pulmonary embolism, etc.) 3. Requires inpatients hospitalization or prolongation of hospitalization 4. Results in clinically significant abnormal laboratory test results or abnormal vital signs, based on clinical judgment.

Time frame: Within one month post infusion

Secondary Outcomes

Difference in rate of decline of Frailty

Difference in rate of decline of Frailty assessed using Fried phenotype scale: 1. Slowing of Mobility (assessed via a 4-meter gait speed test; Timed up and go (TUG) test and Short Physical Performance Battery (SPPB) assessment) 2. Weight Loss (assessed via weighing scale) 3. Reduced Activity (assessed via Minnesota Leisure Time Activities (MLTA) questionnaire) 4. Diminished handgrip strength (assessed via dynamometer) 5. Exhaustion (assessed by two items from the Center for Epidemiological Studies-Depression, CES-D):" I felt that everything I did was an effort? and I could not get going."

Time frame: Baseline, month 1, 3 month and 6 months post infusion

Difference in subject quality of life assessments

Health-related quality of life will be assessed via Short-Form 36 Health Survey (SF-36), including physical functioning scale and mental health index; the health status including Health State Index (HSI) and respondent's self-rated health on a vertical scale will be accessed via EuroQol 5-Dimension (ED-5D).

Time frame: Baseline, month 1, month 3 and month 6 post infusion

Changes in the pro-inflammatory cytokines of blood sample between the HUC-MSC and placebo cohorts

Enzyme-linked immunosorbent assay will be used to identify the serum levels of pro-inflammatory cytokines (e.g.,Interleukin-6).

Time frame: Baseline, month 1, month 3 and month 6 post infusion

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.